11 February 2026
11 February 2026
AstraZeneca’s cancer medicine sales rose 14% in 2025, with upcoming disease expansions a foundation for further growth in 2026.
Analysts said that Yeztugo’s forecast, which would represent 433% year-over-year growth, is achievable.
AbbVie’s latest agreement with the Trump administration underscores a major shift in US drug pricing policy, one in which domestic manufacturing is no longer a peripheral concern but it is built into the deal itself.
Under the agreement, Insilico Medicine will receive R&D funding for each programme.
THX Pharma is set to receive total payments up to $206.1m.
REGENXBIO plans to request a Type A meeting with the FDA to discuss the CRL and its planned BLA resubmission.
The partnership aims to advance high-priority small molecule programmes using Iambic’s AI models and wet lab capabilities.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
